MPL-7097, an ESM™ p38 MAPK inhibitor

- TAMs contribute to enhanced malignancy in multiple cancers by generating an immunosuppressive microenvironment.
- Polarization to a pro-inflammatory M1 phenotype is capable of activating an anti-tumour immune response.
- p38 MAPK plays a role in polarising macrophages towards an immunosuppressive M2 phenotype.
- Pro-inflammatory effect in other immune cells such as T-cells.

ESM™ Technology:
- Human carboxylesterase, hCE-1 expression is largely restricted to cells of the monocyte lineage.
- Macrophage Pharma’s ESM™ technology uses esters that are selectively hydrolysed by hCE-1.
- Accumulation of the active acid occurs in hCE-1 +ve cells.
- **MPL-7097**, an ESM™ p38 MAPK inhibitor, was designed to selectively target macrophages.